Third mRNA COVID-19 vaccine CureVac on the cusp of announcing clinical trial results
Updated: 2021-05-07 13:51:47 KST
Another vaccine is likely on the way, this one developed by the German company Curevac, which could help ease the pressure on supplies around the world.
The Curevac product uses mRNA to trigger an immune response, like the ones from Pfizer and Moderna.
It's awaiting the results of a late-stage clinical trial, which could come as soon as next week.
The two other mRNA vaccines by Pfizer and Moderna have high efficacy rates, but Curevac has an advantage in that it can be stored at a normal refrigerator temperature, rather than the extreme cold required by the Pfizer jab.